Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • mruyog mruyog Aug 9, 2013 10:45 AM Flag

    I Find Scarlett To Very Enthusistic And Confident About Imetelstat

    His responses to the Piper Jeffrey and Stfel Nicolaus guys' questions clearly show Scarlett's personal confidence in the success of Imtelstat for the myeloid application, beating all competition. To quote, "I think this is quite a different product. It is a product that is given by infusion. Most of the other -- for example, JAK inhibitors are oral agents. As we've sort of harped on, we think that there is at least the potential for disease modification, meaningful disease modification. I think the history of most of this JAK inhibitor is not to throw cold water on them. If I had MF, I want to be taking one today. But nevertheless, they haven't shown themselves to be very effective in addressing the underlying malignant clone and malignant disease. And so I think it's quite -- this is quite a unique drug, and so we'll have to see the -- I think we'll have to all see the full profile, and then I think it will become fairly evident where it sits in the competitive landscape."

    Later, while responding to the SN guy, his confidence in Imetelstat achieving PR (partial remission) or even CR (complete remission) of the disease and bringing bone marrow to its normal condition (which no curent drug can attain) is very evident. This kind of confidence was never expressed by him in any of the past CCs.

    With Dr. Tefferi's work, and thus Mayo's stamp of approval, Geron's Imetelstat success is bound to be a reality waiting to reward shareholders.

    I think he has rigthly focussed on Imetelstat in preference to the hESC activity, especilly looking at the financial condition of the company. I have to change my own pessimistic opinion about him and certainly be more optimistic about the company's success now.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GERN
2.69+0.03(+1.13%)Aug 30 4:00 PMEDT